Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.72 |
| ▸ | GRM5 | P41594 | 5/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | CCND1 | P24385 | 2/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22915948 | 0.90 | NAMPT (0.60) | NAMPTGRM5CDK4CCND1HSP90AB1 | |
| SCHEMBL20214405 | 0.87 | NAMPT (0.57) | NAMPTHSP90AB1HTR2CKDM4E | |
| SCHEMBL20214421 | 0.86 | NAMPT (0.56) | NAMPTGRM5CDK4CCND1HTR2C | |
| SCHEMBL17195793 | 0.85 | NAMPT (1.00) | NAMPT | |
| SCHEMBL20214656 | 0.84 | NAMPT (0.54) | NAMPTHTR2C | |
| SCHEMBL20214414 | 0.78 | SMN1; SMN2 (0.57) | NAMPTGRM5CDK4CCND1KDM4E | |
| SCHEMBL13505458 | 0.77 | NAMPT (0.48) | NAMPTHTR2CKDM4E | |
| SCHEMBL24062095 | 0.76 | NAMPT (0.47) | NAMPTGRM5HSP90AB1KDM4E | |
| SCHEMBL22915970 | 0.76 | POLB (0.55) | NAMPTGRM5CDK4CCND1HTR2C | |
| SCHEMBL20213867 | 0.76 | CDK4 (0.56) | NAMPTGRM5CDK4CCND1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
| EP-3548613-A1 | BACTERIAL GLUTAMINYL CYCLASES AND INHIBITORS THEREOF FOR USE IN THE TREATMENT OF PERIODONTITIS | Fraunhofer Gesellschaft zur Förderung der Angewand (DE) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018100159-A1 | BACTERIAL GLUTAMINYL CYCLASES AND INHIBITORS THEREOF FOR USE IN THE TREATMENT OF PERIODONTITIS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | NAMPT 1158/4885GRM5 540/4885CDK4 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.